ArticleAIMS neuroscience2026
Berberine targets the STAT3 signaling pathway to improve cognitive impairment in chronic cerebral hypoperfusion rats.
Article in AIMS neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine (BBR) possesses varied pharmacological properties, including anti-apoptotic and potent neuroprotective effects, and can ameliorate cognitive impairments associated with diverse diseases. Despite the noted potential of BBR in mitigating cognitive deficits associated with chronic cerebral hypoperfusion (CCH), the precise mechanisms underlying its therapeutic effects remain inadequately defined. To explore these mechanisms, a CCH rat model was developed using a refined micro-spring method for bilateral common carotid artery stenosis (BCAS). For the experimental setup, rats were systematically divided into six groups: a Sham group (n = 15), a Sham + BBR group (n = 15), a BCAS group (n = 15), a BCAS + BBR group (n = 15), a BCAS + BBR + Colivelin group (with Colivelin serving as a STAT3 activator, n = 15), and a BCAS + AG490 group (AG490 acting as a JAK2 inhibitor, n = 15). Cognitive performance was evaluated through the Morris water maze and novel object recognition (NOR) tests. Additionally, neuronal integrity was assessed by Nissl and TUNEL staining within the hippocampal region. The study further examined the protein expressions of JAK2, STAT3, phosphorylated JAK2, phosphorylated STAT3, and cleaved caspase-3 using western blot analysis. Interaction targets of BBR were predicted through the STITCH database, and its binding affinity to STAT3 was confirmed using molecular docking and surface plasmon resonance (SPR) techniques. The findings indicated an increase in apoptosis and a decline in cognitive abilities among the hippocampal neurons of the BCAS model rats. These deleterious effects, however, were substantially alleviated following treatment with BBR. The study posits that BBR primarily exerts its neuroprotective effects through the inhibition of the JAK2/STAT3 pathway. Notably, while the activation of this pathway by Colivelin exacerbated neuronal damage and cognitive decline, its inhibition via AG490 markedly decreased apoptosis and improved cognitive outcomes. Therefore, this research suggests that BBR enhances cognitive functions in BCAS rats predominantly by reducing apoptosis in hippocampal neurons through the modulation of the JAK2/STAT3 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.